BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2765094)

  • 1. M-VAC or MVC for the treatment of advanced transitional cell carcinoma: metastatic, induction, and adjuvant.
    Soloway MS; Ishikawa S; Taylor T; Ezell G
    J Surg Oncol Suppl; 1989; 1():40-5. PubMed ID: 2765094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
    Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern.
    Connor JP; Olsson CA; Benson MC; Rapoport F; Sawczuk IS
    Urology; 1989 Dec; 34(6):353-6. PubMed ID: 2595880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
    Higano CS; Tangen CM; Sakr WA; Faulkner J; Rivkin SE; Meyers FJ; Hussain M; Baker LH; Russell KJ; Crawford ED;
    Cancer; 2008 May; 112(10):2181-7. PubMed ID: 18404692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder.
    Miller RJ; Bahnson RR; Banner B; Ernstoff MS; O'Donnell WF
    Cancer; 1990 Jan; 65(2):207-10. PubMed ID: 2295043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M; Kotake T
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
    Miller RS; Torti FM
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder.
    Sternberg CN; Arena MG; Calabresi F; De Carli P; Platania A; Zeuli M; Giannarelli D; Cancrini A; Pansadoro V
    Cancer; 1993 Sep; 72(6):1975-82. PubMed ID: 8364877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study.
    Dreicer R; Messing EM; Loehrer PJ; Trump DL
    J Urol; 1990 Nov; 144(5):1123-6; discussion 1126-7. PubMed ID: 2231884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder.
    Sternberg CN; Pansadoro V; Calabro F; Marini L; van Rijn A; Carli PD; Giannarelli D; Platania A; Rossetti A
    Ann Oncol; 1999 Nov; 10(11):1301-5. PubMed ID: 10631456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
    Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy for invasive bladder carcinoma: disease outcome and bladder preservation and relationship to local tumor response.
    Hatcher PA; Hahn RG; Richardson RL; Zincke H
    Eur Urol; 1994; 25(3):209-15. PubMed ID: 8200403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic changes of transitional cell carcinoma of bladder after M-VAC chemotherapy.
    Javadpour N; Daloni P
    Urology; 1989 Dec; 34(6):357-9. PubMed ID: 2595881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers.
    Ogawa T; Gotoh A; Takenaka A; Hara I; Gohji K; Arakawa S; Matsumoto O; Kamidono S
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S66-71. PubMed ID: 1394822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
    Kobayashi H; Obata K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S14-7. PubMed ID: 7994781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.